March 2, 2021
Swiss drug maker Idorsia Pharmaceuticals said on March 1 that it has submitted a new drug application for clazosentan, a fast-acting selective endothelin A (ET A ) receptor antagonist, to Japanese regulatory authorities. The drug was filed for the prevention...read more